Table 3.

Number (%) of patients who had at least one adverse event with onset during treatment (safety population)

	AZD0837 150 mg od (n = 164)	AZD0837 300 mg od (n = 151)	AZD0837 450 mg od (n = 156)	AZD0837 200 mg bid (n = 160)	VKA INR 2–3 (n = 318)
Mean exposure, days	141	144	145	138	161
Adverse events	96 (58.5)	88 (58.3)	92 (59.0)	92 (57.5)	197 (61.9)
Adverse events leading to discontinuation of study treatment	11 (6.7)	11 (7.3)	16 (10.3)	20 (12.5)	5 (1.6)
Serious adverse events	11 (6.7)	17 (11.3)	25 (16.0)	23 (14.4)	38 (11.9)
Deaths	1 (0.6)	0 (0.0)	0 (0.0)	0 (0.0)	2 (0.6)

INR, international normalized ratio; VKA, vitamin K antagonists.

Patients with multiple events in one category are counted once in that category.

Patients with events in more than one category are counted once in each of those categories.